Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK)

165,800 +6,000 (+3,75%) Alla chiusura: 04:08PM HKT

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

No. 666 Xinhua Avenue
Chengdu Cross-Strait Science and Technology Industry Development Park Wenjiang District
Chengdu
China

https://kelun-biotech.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 1.415

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Junyou Ge	President, CEO, COO, GM & Executive Director	3,83M	N/D	1972
Mr. Zejian Zhou	CFO & Joint Company Secretary	N/D	N/D	1983
Mr. Yong Guo	Deputy GM, Chief Commercial Officer & Chief Marketing Officer	N/D	N/D	1970
Mr. Yi Feng	Deputy GM, Chief Strategy Officer & Senior VP	N/D	N/D	1966
Dr. Xiangyang Tan	Deputy GM and Chief Scientific Officer of Biologics' Research & Development	N/D	N/D	1963
Dr. Xiaoping Jin	Deputy GM & Chief Medical Officer	N/D	N/D	1978
Ms. Wai Sum Fung A.C.I.S., A.C.S.	Joint Company Secretary	N/D	N/D	1983

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in HKD.

Descrizione

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs to address unmet medical needs in the People's Republic of China and internationally. The company is developing various drugs to treat breast, non-small cell lung, and gastrointestinal cancer, as well as non-oncology diseases. Its product pipeline includes oncology drug candidates, such as SKB264 (sacituzumab tirumotecan), A166 (trastuzumab botidotin), SKB315, A167 (tagitanlimab), A140, and A400; and non-oncology drug candidates primarily to treat immune-mediated diseases, consisting of rheumatoid arthritis and alopecia areata comprising A223, A277, SKB378, and SKB336. The company has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; and Ellipses Pharma Limited. The company was incorporated in 2016 and is headquartered in Chengdu, the People's Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. operates as a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.

Governance aziendale

L'ISS Governance QualityScore di Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.